info@biomedres.us   +1 (720) 414-3554   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Research ArticleOpen Access

Inhibitors to Von Willebrand Factor in Type 3 Von Willebrand Disease (VWD)

Hassan M Yaish1*, Robert Christiansen1, Jessica Meznarich1, Walid K Salah2, George Rodgers1 and Richard Lemons1s

DOI: 10.26717/BJSTR.2017.01.000242

  • Author Information Open or Close
    • 1Department of Pediatrics, university of Utah, USA
    • 2Duke University, USA

    Corresponding author: Hassan M Yaish, Department of Pediatrics, university of Utah, school of Medicine, Salt Lake City, UT 84113, USA

Received: July 20, 2017;   Published: August 01, 2017

To view the Full Article   Peer-reviewed Article PDF

Abstract

Type 3 VWD is the least common and most severe among the three types of VWD. The incidence was estimated at 5-3/million and the severity is thought to be similar to mild or moderate hemophilia A. In a recent report from the UK showing that some hemostasis laboratories may fail to perform all required assays for the diagnosis of VWD Type 3, which occasionally result in giving a wrong diagnosis such as mild or moderate hemophilia A. [1] Type 3 VWD is usually associated with a clinical course that combines the bleeding features seen in patients with VWD as well as those encountered in patients with mild to moderate hemophilia.

Introduction| Objectives| Methods| Results| Conclusion| References|